# Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

> **NCT06132503** · PHASE1 · RECRUITING · sponsor: **Lantern Pharma Inc.** · enrollment: 110 (estimated)

## Conditions studied

- Relapsed or Refractory Lymphomas
- Advanced Solid Tumor

## Interventions

- **DRUG:** LP-284

## Key facts

- **NCT ID:** NCT06132503
- **Lead sponsor:** Lantern Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-03
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132503, "Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06132503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*